Literature DB >> 30468509

Probiotics, prebiotics and synbiotics for weight loss and metabolic syndrome in the microbiome era.

R Ferrarese1, E R Ceresola, A Preti, F Canducci.   

Abstract

OBJECTIVE: Excessive body fat and the associated dysmetabolic consequences affect both developed and emerging countries. An altered gut microbiota composition is an important environmental cause of these conditions. Clinical trials targeting gut microbiome composition or functions with pro or prebiotics to promote a healthier profile are considered a promising tool for excessive body weight treatment and prevention of dysmetabolic complications.
MATERIALS AND METHODS: We searched PubMed and Cochrane Library using combinations of probiotics/prebiotics and synbiotics with obesity/weight loss/metabolic syndrome as the search terms. Clinical studies and significant pre-clinical results showing molecular mechanisms supporting clinical results were also discussed.
RESULTS: Several studies in humans and in animal models have elucidated biological mechanisms supporting the observed clinical efficacy of selected probiotic and prebiotic compounds for weight management. Efficacy appears to be species or strain-specific. Fibers such as inulin or galactomannan promote independent and synergistic beneficial effects.
CONCLUSIONS: Diet supplementation with synbiotics prepared using selected strains (such as Lactobacillus gasseri strains) showed to exert weight-reduction and anti-inflammatory activity in large independent studies. Their administration, together with galactomannan and/or inulin fibers, may increase weight management effects due to synergistic effect on short chain fatty acid production and microbiota 're-configuration'.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30468509     DOI: 10.26355/eurrev_201811_16301

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  21 in total

Review 1.  Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.

Authors:  Natalia Vallianou; Theodora Stratigou; Gerasimos Socrates Christodoulatos; Maria Dalamaga
Journal:  Curr Obes Rep       Date:  2019-09

Review 2.  Microbiome diurnal rhythmicity and its impact on host physiology and disease risk.

Authors:  Samuel Philip Nobs; Timur Tuganbaev; Eran Elinav
Journal:  EMBO Rep       Date:  2019-03-15       Impact factor: 8.807

3.  Obesity and Fat Metabolism in Human Immunodeficiency Virus-Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications.

Authors:  Catherine Godfrey; Andrew Bremer; Diana Alba; Caroline Apovian; John R Koethe; Suneil Koliwad; Dorothy Lewis; Janet Lo; Grace A McComsey; Allison Eckard; Suman Srinivasa; Janine Trevillyan; Clovis Palmer; Steven Grinspoon
Journal:  J Infect Dis       Date:  2019-07-02       Impact factor: 5.226

Review 4.  SSAT State-of-the-Art Conference: Advancements in the Microbiome.

Authors:  Miquell O Miller; Purna C Kashyap; Sarah L Becker; Ryan M Thomas; Richard A Hodin; George Miller; Mautin Hundeyin; Smruti Pushalkar; Deirdre Cohen; Deepak Saxena; Benjamin D Shogan; Gareth J Morris-Stiff
Journal:  J Gastrointest Surg       Date:  2021-07       Impact factor: 3.452

Review 5.  Obesity I: Overview and molecular and biochemical mechanisms.

Authors:  Robert H Lustig; David Collier; Christopher Kassotis; Troy A Roepke; Min Ji Kim; Etienne Blanc; Robert Barouki; Amita Bansal; Matthew C Cave; Saurabh Chatterjee; Mahua Choudhury; Michael Gilbertson; Dominique Lagadic-Gossmann; Sarah Howard; Lars Lind; Craig R Tomlinson; Jan Vondracek; Jerrold J Heindel
Journal:  Biochem Pharmacol       Date:  2022-04-05       Impact factor: 6.100

6.  Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial.

Authors:  Arrigo F G Cicero; Federica Fogacci; Marilisa Bove; Marina Giovannini; Claudio Borghi
Journal:  Eur J Nutr       Date:  2020-05-16       Impact factor: 5.614

7.  Dietary intervention using (1,3)/(1,6)-β-glucan, a fungus-derived soluble prebiotic ameliorates high-fat diet-induced metabolic distress and alters beneficially the gut microbiota in mice model.

Authors:  Karthika Muthuramalingam; Vineet Singh; Changmin Choi; Seung In Choi; Young Mee Kim; Tatsuya Unno; Moonjae Cho
Journal:  Eur J Nutr       Date:  2019-10-29       Impact factor: 5.614

Review 8.  Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases.

Authors:  Rosa Vona; Lucrezia Gambardella; Camilla Cittadini; Elisabetta Straface; Donatella Pietraforte
Journal:  Oxid Med Cell Longev       Date:  2019-05-05       Impact factor: 6.543

9.  Metabolomic profiling of oxalate-degrading probiotic Lactobacillus acidophilus and Lactobacillus gasseri.

Authors:  Casey A Chamberlain; Marguerite Hatch; Timothy J Garrett
Journal:  PLoS One       Date:  2019-09-23       Impact factor: 3.240

10.  Effects of Synbiotic Supplement on Human Gut Microbiota, Body Composition and Weight Loss in Obesity.

Authors:  Igor N Sergeev; Thamer Aljutaily; Gemma Walton; Eduardo Huarte
Journal:  Nutrients       Date:  2020-01-15       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.